Prasugrel monotherapy versus standard dual antiplatelet therapy (DAPT) in STEMI patients with optical coherence tomography (OCT)-guided or angio-guided complete revascularisation: design and rationale of the randomised, multifactorial COMPARE STEMI ONE trial
Study context
- Population
- ST-segment elevation myocardial infarction (STEMI) patientsplanned enrolment
- Participants
- 1,656 participants
- Planned comparison
- Prasugrel monotherapy after 1 month of DAPT, as compared to standard 12-month prasugrel-based DAPT, will be tested for non-inferiority; OCT-guided versus angiography-guided staged complete revascularisation
- Primary endpoint
- net adverse clinical events - defined as all-cause death, myocardial infarction, stroke, or Bleeding Academic Research Consortium Type 3 or 5 bleeding events
- Follow-up
- 11 months after randomisation
Methodological detailsdesign and rationale, multifactorial, ancillary substudy
- Design and rationale
- Multifactorial
- Ancillary substudy
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Prasugrel monotherapy versus standard DAPT in STEMI patients with OCT-guided or angio-guided complete revascularisation: design and rationale of the randomised, multifactorial COMPARE STEMI ONE trial. EuroIntervention. Published 16 May 2025. doi:10.
Summarised from the published abstract; every number is checked against it